ARS Pharmaceuticals (SPRY) Stock Forecast & Price Target

Compare

434 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SPRY Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

ARS

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SPRY Stock 12 Month Forecast

Average Price Target

$30.00

▲(123.21% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for ARS Pharmaceuticals in the last 3 months. The average price target is $30.00 with a high forecast of $32.00 and a low forecast of $28.00. The average price target represents a 123.21% change from the last price of $13.44.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","20":"$20","33":"$33","13.5":"$13.5","26.5":"$26.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$28.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,13.5,20,26.5,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.18,18.32,19.46,20.6,21.740000000000002,22.880000000000003,24.02,25.16,26.3,27.44,28.580000000000002,29.72,30.86,{"y":32,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.18,18.166153846153847,19.15230769230769,20.138461538461538,21.124615384615385,22.11076923076923,23.096923076923076,24.083076923076923,25.06923076923077,26.055384615384614,27.04153846153846,28.027692307692305,29.013846153846153,{"y":30,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.18,18.012307692307694,18.844615384615384,19.676923076923078,20.50923076923077,21.341538461538462,22.173846153846153,23.006153846153847,23.838461538461537,24.67076923076923,25.503076923076925,26.335384615384616,27.167692307692306,{"y":28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.88,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.73,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.49,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.46,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.26,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.32,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.55,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.02,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.48,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.46,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.09,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.18,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$32.00

Average Price Target$30.00

Lowest Price Target$28.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Dex Genotek

TR | OpenAI - 4o

$13.5

Hold

0.45%

Upside

Reiterated

08/28/25

AI Generated ArticleAI Generated Article

Lachlan Hanbury Brown

William Blair

―

Buy

―

Reiterated

08/20/25

ARS Pharmaceuticals: Strong Market Position and Growth Potential Justify Buy Rating9:38 AM Research | Healthcare ARS Pharmaceuticals, Inc. (SPRY) $13.79 Market Value (M): $1,363 Biotechnology Lachlan Hanbury-Brown +1 312 364 8125 lhanbury- Neffy Growth and Share Gains Continue Into Peak Season; Recent Weakness Presents Buying Opportunity On Tuesday, August 19, we hosted investor meetings with management of ARS Pharmaceuticals including CEO Justin Chakma. The discussions primarily focused on the company’s ongoing launch of neffy in the U.S., including updates on its marketing and sales initiatives to drive neffy awareness and adoption, market access, expectations for the coming quarters, and the recent stock weakness after reporting a solid second-quarter performance last week.

Ryan Deschner

Raymond James

$32

Buy

138.10%

Upside

Reiterated

08/14/25

Raymond James Sticks to Their Buy Rating for ARS Pharmaceuticals (SPRY)

Roanna Ruiz

Leerink Partners

$28

Buy

108.33%

Upside

Reiterated

08/14/25

Leerink Partners Sticks to Their Buy Rating for ARS Pharmaceuticals (SPRY)

Louise Chen

Scotiabank

$30

Buy

123.21%

Upside

Reiterated

05/15/25

Analysts' Top Healthcare Picks: ARS Pharmaceuticals (SPRY), Gain Therapeutics (GANX)

Joshua Schimmer

Cantor Fitzgerald

$35→$30

Buy

123.21%

Upside

Reiterated

03/20/25

ARS Pharmaceuticals Inc (SPRY) PT Lowered to $30 at Cantor FitzgeraldCantor Fitzgerald analyst Josh Schimmer lowered the price target on ARS Pharmaceuticals Inc (NASDAQ: SPRY) to $30.00 (from $35.00) while maintaining a Overweight rating.

Andreas Argyrides

Oppenheimer

$40

Buy

197.62%

Upside

Initiated

02/10/25

ARS Pharmaceuticals initiated with an Outperform at OppenheimerARS Pharmaceuticals initiated with an Outperform at Oppenheimer

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$40

Buy

197.62%

Upside

Initiated

02/10/25

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Dex Genotek

TR | OpenAI - 4o

$13.5

Hold

0.45%

Upside

Reiterated

08/28/25

AI Generated ArticleAI Generated Article

Lachlan Hanbury Brown

William Blair

―

Buy

―

Reiterated

08/20/25

Ryan Deschner

Raymond James

$32

Buy

138.10%

Upside

Reiterated

08/14/25

Raymond James Sticks to Their Buy Rating for ARS Pharmaceuticals (SPRY)

Roanna Ruiz

Leerink Partners

$28

Buy

108.33%

Upside

Reiterated

08/14/25

Leerink Partners Sticks to Their Buy Rating for ARS Pharmaceuticals (SPRY)

Louise Chen

Scotiabank

$30

Buy

123.21%

Upside

Reiterated

05/15/25

Analysts' Top Healthcare Picks: ARS Pharmaceuticals (SPRY), Gain Therapeutics (GANX)

Joshua Schimmer

Cantor Fitzgerald

$35→$30

Buy

123.21%

Upside

Reiterated

03/20/25

Andreas Argyrides

Oppenheimer

$40

Buy

197.62%

Upside

Initiated

02/10/25

ARS Pharmaceuticals initiated with an Outperform at OppenheimerARS Pharmaceuticals initiated with an Outperform at Oppenheimer

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$40

Buy

197.62%

Upside

Initiated

02/10/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ARS Pharmaceuticals

1 Month

xxx

Success Rate

6/7 ratings generated profit

Average Return

+9.10%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 85.71% of your transactions generating a profit, with an average return of +9.10% per trade.

3 Months

xxx

Success Rate

5/7 ratings generated profit

Average Return

+16.06%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +16.06% per trade.

1 Year

Andreas ArgyridesOppenheimer

Success Rate

8/10 ratings generated profit

Average Return

+100.57%

initiated a buy rating 7 months ago

Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +100.57% per trade.

2 Years

xxx

Success Rate

10/10 ratings generated profit

Average Return

+140.84%

initiated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +140.84% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SPRY Analyst Recommendation Trends

Rating

Mar 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SPRY has received 7 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. SPRY average Analyst price target in the past 3 months is 30.00.

Each month's total comprises the sum of three months' worth of ratings.

SPRY Financial Forecast

SPRY Earnings Forecast

Next quarter’s earnings estimate for SPRY is -$0.46 with a range of -$0.56 to -$0.39. The previous quarter’s EPS was -$0.46. SPRY beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.22% of the time in the same period. In the last calendar year SPRY has Outperformed its overall industry.

SPRY Sales Forecast

Next quarter’s sales forecast for SPRY is $26.80M with a range of $18.00M to $32.49M. The previous quarter’s sales results were $15.72M. SPRY beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.92% of the time in the same period. In the last calendar year SPRY has Outperformed its overall industry.

SPRY Stock Forecast FAQ

What is SPRY’s average 12-month price target, according to analysts?

Based on analyst ratings, Ars Pharmaceuticals, Inc.’s 12-month average price target is 30.00.

What is SPRY’s upside potential, based on the analysts’ average price target?

Ars Pharmaceuticals, Inc. has 123.21% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SPRY a Buy, Sell or Hold?

Ars Pharmaceuticals, Inc. has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is Ars Pharmaceuticals, Inc.’s price target?

The average price target for Ars Pharmaceuticals, Inc. is 30.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $32.00 ,the lowest forecast is $28.00. The average price target represents 123.21% Increase from the current price of $13.44.

What do analysts say about Ars Pharmaceuticals, Inc.?

Ars Pharmaceuticals, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of SPRY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

ARS Pharmaceuticals (SPRY) Stock Forecast & Price Target

SPRY Analyst Ratings

SPRY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering ARS Pharmaceuticals

SPRY Analyst Recommendation Trends

SPRY Financial Forecast

SPRY Earnings Forecast

SPRY Sales Forecast

SPRY Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts